{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:15Z","timestamp":1791563175509,"version":"4.3.4"},"reference-count":33,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0532-1","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T14:04:02Z","timestamp":1550498642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab"],"prefix":"10.1136","volume":"7","author":[{"given":"Hao Chi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"532_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4137\/CMO.S5855","volume":"6","author":"C Lemech","year":"2012","unstructured":"Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 2012;6:53\u201366.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"532_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fon.14.196","volume":"11","author":"Z Reese","year":"2015","unstructured":"Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in the treatment of prostate cancer. Future Oncol. 2015;11(1):27\u201337.","journal-title":"Future Oncol"},{"issue":"21","key":"532_CR3","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"532_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS, MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675\u201382.","journal-title":"Cancer"},{"key":"532_CR5","unstructured":"National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Ipilimumab. 2018. \n                    https:\/\/livertox.nlm.nih.gov\/Ipilimumab.htm\n                    \n                  . Accessed 6 Aug 2018."},{"key":"532_CR6","unstructured":"National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Nivolumab. 2018. \n                    https:\/\/livertox.nlm.nih.gov\/Nivolumab.htm\n                    \n                  . Accessed 6 Aug 2018."},{"issue":"10","key":"532_CR7","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of Adverse Events Following Treatment with Anti-Programmed Death-1 agents. Oncologist. 2016;21(10):1230\u201340.","journal-title":"Oncologist"},{"issue":"1","key":"532_CR8","doi-asserted-by":"publisher","first-page":"00187","DOI":"10.15406\/jcpcr.2016.06.00187","volume":"6","author":"K DeSouza","year":"2016","unstructured":"DeSouza K, Savva C. Management of Immunotherapy Related Adverse Effects. J Cancer Prev Curr Res. 2016;6(1):00187.","journal-title":"J Cancer Prev Curr Res"},{"issue":"6","key":"532_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965\u201373.","journal-title":"Mod Pathol"},{"issue":"15_suppl","key":"532_CR10","doi-asserted-by":"publisher","first-page":"8583","DOI":"10.1200\/jco.2011.29.15_suppl.8583","volume":"29","author":"RA Ibrahim","year":"2011","unstructured":"Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol. 2011;29(15_suppl):8583.","journal-title":"J Clin Oncol"},{"issue":"14","key":"532_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.21037\/atm.2016.07.10","volume":"4","author":"H Linardou","year":"2016","unstructured":"Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4(14):272.","journal-title":"Ann Transl Med"},{"key":"532_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"6","key":"532_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38(6):976\u201387.","journal-title":"Liver Int"},{"issue":"4","key":"532_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013;31(4):1071\u20137.","journal-title":"Investig New Drugs"},{"issue":"1","key":"532_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71\u201383.","journal-title":"Ann Oncol"},{"issue":"1","key":"532_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"532_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E Martin De","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181\u201390.","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"532_CR18","first-page":"30","volume":"28","author":"BA Teply","year":"2014","unstructured":"Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28(Suppl 3):30\u20138.","journal-title":"Oncology (Williston Park)"},{"issue":"15","key":"532_CR19","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with Cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283\u20139.","journal-title":"J Clin Oncol"},{"key":"532_CR20","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s10620-009-0839-8","volume":"55","author":"JD Lord","year":"2010","unstructured":"Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci. 2010;55:1396\u2013405.","journal-title":"Dig Dis Sci"},{"key":"532_CR21","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","volume":"54","author":"RL Johnston","year":"2009","unstructured":"Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538\u201340.","journal-title":"Dig Dis Sci"},{"key":"532_CR22","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1245\/s10434-008-0104-y","volume":"15","author":"GQ Phan","year":"2008","unstructured":"Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol. 2008;15:3014\u201321.","journal-title":"Ann Surg Oncol"},{"key":"532_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/cbr.2008.0607","volume":"24","author":"DR Minor","year":"2009","unstructured":"Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24:321\u20135.","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"532_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","volume":"23","author":"C Pag\u00e8s","year":"2013","unstructured":"Pag\u00e8s C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227\u201330.","journal-title":"Melanoma Res"},{"issue":"46","key":"532_CR25","doi-asserted-by":"publisher","first-page":"17352","DOI":"10.3748\/wjg.v20.i46.17352","volume":"20","author":"RE Rossi","year":"2014","unstructured":"Rossi RE, Parisi I, Despott EJ, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20(46):17352\u20139.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"532_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11739-009-0342-4","volume":"5","author":"S Mancini","year":"2010","unstructured":"Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193\u2013200.","journal-title":"Intern Emerg Med"},{"issue":"7","key":"532_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/MEG.0000000000000624","volume":"28","author":"I Parisi","year":"2016","unstructured":"Parisi I, O'Beirne J, Rossi RE, et al. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. Eur J Gastroenterol Hepatol. 2016;28(7):786\u201391.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"532_CR28","unstructured":"National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Infliximab. 2018. \n                    https:\/\/livertox.nlm.nih.gov\/Infliximab.htm\n                    \n                  . Accessed 6 Aug 2018."},{"issue":"7","key":"532_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","unstructured":"Bj\u00f6rnsson ES, Bergmann OM, Bj\u00f6rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419\u201325.","journal-title":"Gastroenterology"},{"issue":"3","key":"532_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","volume":"13","author":"ES Bj\u00f6rnsson","year":"2015","unstructured":"Bj\u00f6rnsson ES, Gunnarsson BI, Gr\u00f6ndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"532_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonz\u00e1lez-Huix F, Suarez F, Forn\u00e9 M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53(9):1363\u20135.","journal-title":"Gut"},{"issue":"5","key":"532_CR32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.crohns.2012.01.017","volume":"6","author":"C Casteren-Messidoro van","year":"2012","unstructured":"van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6(5):630\u20131.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"532_CR33","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57(8):2233\u201340.","journal-title":"Dig Dis Sci"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0532-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:49Z","timestamp":1601056009000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0532-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0532-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics approval of this study was granted by the IRB committee at the University of Texas MD Anderson Cancer Center (PA18\u20130472). The consent was waived for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}